USFDA concludes inspection at Shilpa Medicare’s Bengaluru unit

31 Oct 2024 Evaluate

The U.S Food and Drug Administration (USFDA) has concluded inspection at Shilpa Medicare’s Unit VI, Dabaspet, Bengaluru, India. The inspection concluded with the issuance of Form 483 with four observations. All observations are procedural in nature. The company shall respond to the observations within the time frame. The said unit was inspected by USFDA on October 24, 25 and 28, 29, 30, 2024. The inspection was the onsite GMP inspection of this Site. 

This Unit of Shilpa Medicare is engaged in the manufacturing, testing and release of Oral Mouth Dissolving Films and Transdermal Systems. The Site has already been approved by MHRA-UK and TGA Australia and has USFDA approval for supplying nutraceutical Oral Film products into US and other markets.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

319.85 -0.65 (-0.20%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×